Celltrion nabs Herceptin biosim nod in S. Korea; Hungary approves Novartis' generic Advair;

@FiercePharma: FDA: The social media guidance puzzle will be complete by July. More | Follow @FiercePharma

@TracyStaton: Hungary joins the club of EU countries approving Novartis' generic version of GSK's blockbuster Advair. News | Follow @TracyStaton

@EricPFierce: FDA investigator assigned to Europol to fight fakes being hawked online by drug rings. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: Allergan rides high on patent backing for key drugs Lumigan and Restasis. Article | Follow @CarlyHFierce

> South Korea's Celltrion won regulatory approval in its home country for Herzuma, its biosimilar version of Roche's ($RHHBY) original breast cancer blockbuster, Herceptin. Report

> Hungary became the latest EU country to approve AirFluSal Forspiro, a generic version of GlaxoSmithKline's ($GSK) blockbuster lung drug Advair made by Novartis' ($NVS) generics unit, Sandoz. Report

> Amarin ($AMRN) said the FDA delayed a decision on a large, late-stage trial of its Vascepa blood-lipid drug; it's the latest obstacle for Amarin in its quest to win approval to market the drug to a broader group of patients. Release |  Report

> Novo Nordisk ($NVO) made Fortune's latest list of the 100 best companies to work for, ranked 72nd. Release

> Amgen ($AMGN) teamed up with the gene-sequencing specialist Illumina ($ILMN) to develop a diagnostic test to identify patients for its targeted colon cancer drug Vectibix. Report

> Allergan ($AGN) CEO David Pyott says he's not interested in buying an Irish company to lower his company's corporate taxes. Report

Medical Device News

@FierceMedDev: Thermo nabs Chinese approval of $13.6B Life Tech merger. More | Follow @FierceMedDev

@MarkHFierce: Even N.Y. Sen. Chuck Schumer spilled the beans about Carlyle Group's bid for J&J's Ortho Clinical diagnostics arm. Story | Follow @MarkHFierce

@MichaelGFierce: Cynapsus' sublingual strip for severe Parkinson's reduces side effects in a study. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Integra finalizes $235M deal for Covidien's surgical products line. News | Follow @EmilyWFierce

@GalenMoore: Bio-Path Holdings is raising $10M for its cancer drug delivery tech. Release | Follow @GalenMoore

> Medtronic must pay Edwards at least $394M in heart valve patent trial defeat. Report

> Illumina will concoct a companion Dx for an Amgen colon cancer drug. Item

> Fallout from Orthofix's Medicare kickback scandal takes down a VA podiatrist. More

Biotech News

@FierceBiotech: Merck clears an FDA panel with its clot-fighting vorapaxar. Story | Follow @FierceBiotech

@JohnCFierce: ICYMI: Roche's dealmakers at pRED will continue their global shopping spree in 2014. More | Follow @JohnCFierce

@DamianFierce: Sarepta still climbing on renewed hopes for eteplirsen. Article | Follow @DamianFierce

@EmilyMFierce: Per the FDA's new stance on antibacterials, here's a list of household products containing triclosan. | Follow @EmilyMFierce

> Amarin endures another FDA delay as Vascepa languishes. More

> J&J shipping out diagnostics biz for $4.2B. Report

> Gentium shareholders cry foul on $1B Jazz deal. News

Pharma Manufacturing News

> Merck recalls all lots of Liptruzet shipped since its May debut. Story

> Former Fresenius employee says he was fired for raising red flags. Article

> Premier supports new FDA compounder oversight plan. Report

> FDA assigns an agent to Europol in its fight against fakes. More

> Sources: Ranbaxy asks the FDA to let it make generic Diovan in U.S. News

> Actavis selling China assets as it exits that country. Item

Vaccines News

> CDC, FDA studies link Merck and GSK rotavirus vaccines to bowel blockages. Story

> BIO and Sanofi are pushing the FDA to tweak its drug shortage rule for vaccines. Story

> A Dendreon consultant has raised $8M for a cancer vaccine startup. Story

> Buzz: Merck and Novartis trying to iron out details of their business unit swap. Story

> AC Immune begins first trial of a tau-targeting Alzheimer's vaccine. Story

> Astellas and Takeda continue to advance vaccine strategies. Item

And Finally... Rotavirus vaccines from Merck ($MRK) and GlaxoSmithKline ($GSK) may carry a small risk of a type of bowel obstruction, but not enough to change recommendations for their use. Report